Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Palantir Technologies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.88 (market cap $29.60B), while Palantir Technologies Inc trades at $169.07 (market cap $420.39B). The key difference: Palantir Technologies Inc is far larger — about 14.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | PLTR | |
|---|---|---|
Market Cap | $29.60B | $420.39B |
Sector | Health | Technology |
52-Week High | $491.22 | $207.18 |
52-Week Low | $205.48 | $107.27 |
Enterprise Value | $27.56B | $411.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Palantir (PLTR) trades at $175.20, up 1.85% with strong bullish technical signals and consistent earnings beats. The stock shows impressive fundamental growth with revenue reaching $4.48 billion in 2025 and net income margin expanding to 36.3%. Recent quarterly EPS results have exceeded expectations, driving positive investor sentiment despite elevated valuation multiples. Technical indicators show bullish momentum with the current price near pivot point resistance at $175.
Outlook remains positive with accelerating revenue growth and expanding margins, though high valuation ratios (P/E 149.52, P/S 73.07) present risk. Analyst consensus targets $213.44 with 50% buy ratings, but insider selling and Michael Burry's bearish stance highlight caution. The stock offers growth potential but requires monitoring of execution risks and competitive pressures in the AI software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
